Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Cost-Effectiveness Of Ceritinib In Previously Treated Patients With Crizotinib In Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In Canada

Value in Health ◽

10.1016/j.jval.2015.09.1199 ◽

2015 ◽

Vol 18 (7) ◽

pp. A462 ◽

Cited By ~ 1

Author(s):

Z Zhou ◽

M Hurry ◽

J Zhang ◽

L Fan ◽

C Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Previously Treated Patients ◽

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Cited By ~ 3

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

Value in Health ◽

10.1016/j.jval.2020.08.244 ◽

2020 ◽

Vol 23 ◽

pp. S442

Author(s):

G. Gourzoulidis ◽

O. Zisimopoulou ◽

N. Boubouchairopoulou ◽

C. Michailidi ◽

C. Almond ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Crizotinib: a guide to its use in previously treated advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in the EU

Drugs & Therapy Perspectives ◽

10.1007/s40267-013-0015-2 ◽

2013 ◽

Vol 29 (3) ◽

pp. 64-68

Author(s):

Mary Hines ◽

Katherine A. Lyseng-Williamson ◽

Monique P. Curran

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Previously Treated ◽

The Eu

Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?

Journal of Clinical Oncology ◽

10.1200/jco.2013.54.6002 ◽

2014 ◽

Vol 32 (10) ◽

pp. 983-985 ◽

Cited By ~ 9

Author(s):

Ronan J. Kelly ◽

Bruce E. Hillner ◽

Thomas J. Smith

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

The Cost

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study

Annals of Oncology ◽

10.1093/annonc/mdw435.41 ◽

2016 ◽

Vol 27 ◽

pp. vi579 ◽

Cited By ~ 10

Author(s):

G. Scagliotti ◽

T.M. Kim ◽

L. Crinò ◽

G. Liu ◽

C. Gridelli ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Anaplastic Lymphoma ◽

Previously Treated ◽

Confirmatory Phase

Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer

Clinical Drug Investigation ◽

10.1007/s40261-019-00880-8 ◽

2019 ◽

Vol 40 (2) ◽

pp. 183-189 ◽

Cited By ~ 3

Author(s):

Hongchao Li ◽

Lei Lai ◽

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma

Cost-Effectiveness Of Ceritinib In The Treatment Of Previously Treated Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small Cell Lung Cancer In The United Kingdom

Value in Health ◽

10.1016/j.jval.2015.09.1163 ◽

2015 ◽

Vol 18 (7) ◽

pp. A455-A456 ◽

Cited By ~ 5

Author(s):

Z Zhou ◽

J Zhang ◽

L Fan ◽

C Zhang ◽

J Xie

Keyword(s):

Lung Cancer ◽

United Kingdom ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

The United Kingdom ◽

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Drug Design Development and Therapy ◽

10.2147/dddt.s91988 ◽

2015 ◽

pp. 5491

Author(s):

Baoan Chen ◽

Liting Guo ◽

Haijun Zhang ◽

Weiwei Shao

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Anaplastic Lymphoma Kinase Rearrangement ◽

Previously Treated Patients ◽

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study

Cancer Science ◽

10.1111/cas.14576 ◽

2020 ◽

Vol 111 (10) ◽

pp. 3726-3738

Author(s):

Takashi Seto ◽

Hidetoshi Hayashi ◽

Miyako Satouchi ◽

Yasushi Goto ◽

Seiji Niho ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Subgroup Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Global Study ◽